Boston Scientific to Acquire Valencia Technologies, Expanding Bladder Dysfunction Portfolio

The transaction is expected to close in the first half of 2026, subject to customary closing conditions. Financial terms of the deal were not disclosed.

Boston Scientific Corporation has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on treatments for bladder dysfunction.

The transaction is expected to close in the first half of 2026, subject to customary closing conditions. Financial terms of the deal were not disclosed.

Valencia Technologies is best known for its eCoin System, an implantable tibial nerve stimulation (ITNS) device designed to treat urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB). The device received approval from the US Food and Drug Administration in 2022.

Overactive bladder affects a significant portion of the adult population in the United States. Nearly 30 million adults aged 40 years and older experience bothersome OAB symptoms, according to data cited by the company. Beyond behavioral and lifestyle modifications, treatment adoption remains limited, with one study estimating the overall treatment rate at approximately 19%. The condition is associated with reduced quality of life and can affect mental health, sleep, productivity, and social functioning.

The eCoin System is a coin-sized implant placed under the skin near the ankle through a minimally invasive procedure. It is intended for patients who have had a successful trial of percutaneous tibial nerve stimulation (PTNS) or for those who do not tolerate or respond adequately to more conservative treatment options for UUI. Once implanted, the device delivers intermittent, automated stimulation to the tibial nerve, influencing bladder control pathways between the brain and the bladder.

Clinical data from the eCoin pivotal trial showed that 68% of patients experienced at least a 50% reduction in UUI episodes. The device is positioned as a long-term therapy option for patients requiring ongoing neuromodulation-based treatment.

Commenting on the agreement, Meghan Scanlon, senior vice president and president of Urology at Boston Scientific, said, “The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation, a high-growth adjacency for our Urology business.”

Boston Scientific stated that the transaction is expected to have an immaterial impact on adjusted earnings per share in 2026. On a GAAP basis, the acquisition is expected to be more dilutive due to acquisition-related charges and amortization expenses.

The acquisition aligns with Boston Scientific’s ongoing expansion in urology and pelvic health, adding an implantable neuromodulation option to its existing treatment offerings.

Stay tuned for more such updates on Digital Health News